Can I get it?
Yes, if a doctor decides it is right for you. Caverject is authorised in the EU and can be prescribed after a medical review.
CaverjectPrescription only
Online medical consultation for Caverject.
An EU-licensed doctor reviews your case and, if eligible, issues an electronic prescription valid at any EU pharmacy under Directive 2011/24/EU.
- A non-PDE5 route
- Direct, local action
- An option when oral PDE5s don't work or aren't allowed
Start consultationStart consultation · €35
Full refund if a review is not approved · Medication, if prescribed, is dispensed and paid for separately at a pharmacy.
IN PLAIN TERMS
What Caverject is, and how to get treatment
Alprostadil is a copy of prostaglandin E1, a substance the body makes naturally that widens blood vessels. Unlike the tablets, it is applied straight to the penis - as a cream on the tip, as an injection into the side of the shaft, or as a small pellet placed into the urethra - so it acts on the blood vessels directly. It has been authorised in EU countries for erectile dysfunction since 1994 as an injection and since 2014 as a cream. Because it works locally, the main side effects are also local: burning, pain or redness where it is applied, and rarely an erection that lasts too long, which needs urgent medical attention.
Caverject has been authorised for use in the EU since 29 November 1994, so a licensed doctor can prescribe it when it is clinically appropriate for you.
What can I take instead?
Our doctors review every Sexual health option and recommend what fits your history and goals.
See all Sexual health optionsWhat do the studies show?
Every trial behind Caverject is listed below with how many people took part and whether the results are peer-reviewed or a company announcement.
Jump to the studiesVERIFIED EVIDENCE
Caverject: evidence and regulatory guide.
WHAT IT IS
How it works
Alprostadil is a man-made copy of a natural body chemical (prostaglandin E1) that is applied to or injected into the penis, where it widens the blood vessels directly so blood flows in.
DEVELOPMENT STAGE
EU-authorised medicine
Trial register4 registered trials
Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.
| TRIAL / NCT | POPULATION | PARTICIPANTS | STATUS | READOUT / COMPLETION |
|---|---|---|---|---|
| Integrated analysis of two multicentre, double-blind, parallel-group topical-cream studies | Men with an IIEF erectile function domain score of 25 or less, including men with diabetes and men taking organic nitrates | 1,732 | Read out | 2006-08-01 |
| Alprostadil Study Group — intracavernosal dose-response study | Men with erectile dysfunction of vasculogenic, neurogenic, psychogenic and mixed causes | 296 | Read out | 1996-04-04 |
| Alprostadil Study Group — six-month intracavernosal self-injection study | Men with erectile dysfunction of mixed causes | 683 | Read out | 1996-04-04 |
| MUSE Study Group — transurethral alprostadil, double-blind placebo-controlled trial | Men aged 27-88 with chronic erectile dysfunction from various organic causes | 1,511 | Read out | 1997-01-02 |
What the studies reported
Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.
Peer-reviewed
Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology 2006;68(2):386-391. doi:10.1016/j.urology.2006.02.027 (PMID 16904458)| DOSE OR GROUP | MEAN WEIGHT CHANGE | WEEKS |
|---|---|---|
| 100 microgram cream (n=434) | IIEF erectile function domain change from baseline +1.6 points vs -0.7 on placebo (p<0.001) | 12 |
| 200 microgram cream (n=430) | IIEF erectile function domain change from baseline +2.5 points vs -0.7 on placebo (p<0.001) | 12 |
| 300 microgram cream (n=434) | IIEF erectile function domain change from baseline +2.4 points vs -0.7 on placebo (p<0.001) | 12 |
The IIEF changes are small in absolute terms and the authors describe the SEP2 and SEP3 improvements as slight though statistically significant; the studies ran for 12 weeks and cover the topical cream only, not the injected or intraurethral forms.
Sources
Last reviewed 2026-07-27
- AEMPS CIMA — Caverject 20 microgramos (alprostadil, intracavernosal injection), reg. 60535, first authorised in Spain 29 November 1994, indicated for erectile dysfunction
- AEMPS CIMA — Virirec 3 mg/g crema (alprostadil topical), reg. 78357, first authorised April 2014; the same cream was approved via the EU decentralised procedure as Vitaros in 2013
- Urology 2006 — Integrated analysis of alprostadil topical cream in 1,732 patients (PMID 16904458)
- N Engl J Med 1996 — Efficacy and safety of intracavernosal alprostadil (PMID 8596569)
- N Engl J Med 1997 — Treatment of men with erectile dysfunction with transurethral alprostadil, MUSE Study Group (PMID 8970933)
NAMED SAFETY SIGNALS
What has been reported with Caverject.
Application-site burning, penile pain and redness (cream)
Penile burning, penile pain, penile erythema, genital pain and genital discomfort are all listed as common in the EU product information for alprostadil 3 mg/g cream. In the clinical trial the withdrawal rate was 30% in the 300 microgram group compared with 20% in the 200 microgram group.
Injection-site pain (intracavernosal)
Penile pain is listed as very common in the EU product information for alprostadil injection. In the six-month self-injection study, usually mild penile pain occurred in 50% of men at some time but after only 11% of injections.
Prolonged erection and priapism (intracavernosal)
In the EU product information for alprostadil injection, a prolonged erection lasting 4 to 6 hours developed in 4% of patients and priapism (a painful erection lasting more than 6 hours) in 0.4%. In the six-month self-injection study, prolonged erections occurred in 5% of men and priapism in 1%.
Prolonged erection and priapism (cream)
Listed as uncommon in the EU product information for alprostadil cream. Priapism was seen in 1 patient (0.06%) across the two 3-month studies and in 5 patients (0.4%) in the study lasting more than 6 months. An erection lasting more than 4 hours needs immediate medical help, because untreated priapism can permanently damage erectile tissue.
Penile fibrosis (intracavernosal)
Penile fibrosis, including angulation, fibrotic nodules and Peyronie's disease, was reported in 3% of clinical-trial patients in the EU product information for alprostadil injection, rising to about 8% in a self-administration study of up to 18 months. Injection-site haematoma was reported by 3% and bruising by 2%.
Dizziness and fainting
In the phase 3 cream studies, symptomatic low blood pressure (dizziness) and fainting occurred in 0.4%, 0.4% and 0.5% of patients on the 100, 200 and 300 microgram doses. Patients are advised not to drive or do hazardous tasks until they know how they react.
Effects on a female partner
Vulvovaginal burning and vaginitis are listed as common reactions in female partners in the EU product information for alprostadil cream.
Penile pain (intraurethral)
In the transurethral pivotal trial, mild penile pain was the most common side effect, occurring after 10.8% of treatments; in-clinic low blood pressure occurred in 3.3% of men, and no man had priapism or penile fibrosis.
FormUrethral cream or injection
FrequencyOn demand
ResultsDirect local action
What you pay Hi-Doctor€35 one-off
IN 60 SECONDS
Caverject at a glance
- A prostaglandin E1 medicine that widens the blood vessels inside the penis
- Adult men whose erectile dysfunction is unsuited to, or not helped by, oral tablets
- Given as a cream at the tip of the penis, a urethral pellet, or an injection
- An erection lasting 4 hours or more is priapism, and it is a medical emergency
- Hi-Doctor consultation fee; the medicine is paid separately at a pharmacy
BRAND FACTS
Caverject at a glance
Caverject holds national authorisations rather than a centralised EU one; the details here come from the Spanish authorisation (AEMPS registrations 60535 and 60911, holder Pfizer, S.L.), where both strengths are currently marketed. It is injected directly into the penis, so the first dose is normally given and taught in a clinical setting. In the United Kingdom, Pfizer Limited also holds a Caverject Dual Chamber presentation at 10 and 20 micrograms.
- MARKETING AUTHORISATION HOLDER
- Pfizer, S.L.
- EU-AUTHORISED INDICATIONS
- Treatment of erectile dysfunction
- Use alongside other diagnostic tests in the assessment of erectile dysfunction
- PRESENTATIONS
- 10 micrograms powder and solvent for solution for injection · 20 micrograms powder and solvent for solution for injection
About
What is Caverject?
Caverject contains the active ingredient alprostadil.
Active ingredient: Alprostadil · Dosages: Cream 3 mg/g on demand
Alprostadil is a prostaglandin E1 that directly dilates the blood vessels of the penis. It's considered when oral PDE5 inhibitors are ineffective or contraindicated.
It's administered as a urethral cream or an intracavernous injection, under medical instruction — each route has its own efficacy and tolerability profile. Correct technique matters, and the doctor explains the protocol and the warning signs.
HOW IT WORKS
What Caverject does in your body
Rather than blocking an enzyme, alprostadil acts directly on the penile blood vessels, dilating them locally — no PDE5 pathway involved, so it can work where oral options don't.
A copy of prostaglandin E1
Alprostadil is chemically identical to prostaglandin E1, a signalling substance the body already makes. It is not swallowed. It is placed into or onto the penis itself, so it acts on the erectile tissue at the site rather than circulating through the whole body first.
Cavernosal muscle relaxes
The drug relaxes the smooth muscle of the corpora cavernosa, the two spongy cylinders that run the length of the penis, and widens the cavernosal arteries feeding them. Blood flow into the erectile tissue rises, and that increase in flow is what produces rigidity.
It does not need arousal
Because it acts on the tissue directly, alprostadil does not depend on the nitric oxide signal that sexual stimulation produces. In clinic testing it created erections on its own. That is the core difference from tablets, and it is also why an erection can outlast the encounter.
How it helps
How it helps.
A different pathway
Works directly on the blood vessels — not through the PDE5 enzyme.
Local application
Applied where it acts, shortly before intercourse.
Guided by your doctor
Administration technique and warning signs are explained before you start.
What to expect
How to use it.
Prescribed with clear administration instructions. Your doctor explains the protocol, and follow-up happens through your account chat.
- Prescribed with clear administration instructions
- Applied shortly before intercourse
- Correct technique matters — your doctor explains it
- Follow-up and questions through your account chat
Forms your doctor can prescribe
- Urethral cream3 mg/g — on demand
Your schedule is personal
These are typical steps only. Your doctor adjusts the plan to how you respond and tolerate it — and you can message them at any point.
DAY TO DAY
Taking Caverject day to day
Get shown the technique first
Every form of alprostadil has to be demonstrated by a medical professional before you use it yourself. For the injection and the urethral pellet the first doses are given or supervised in a clinic, not at home, and that step cannot be skipped.
Empty your bladder first
Urinate before using the cream or the pellet. A moist urethra helps the medicine dissolve and spread. Do not urinate straight after the cream, because the dose can be washed out before it has had time to work.
Cream sits at the opening
Roll the single-dose container between your hands to warm it, hold the penis upright and squeeze the tip to widen the opening. Place the container at the opening without inserting it, push all the cream in, then hold the penis upright for about 30 seconds.
Pellet needs a stretch and roll
For the urethral pellet, stretch the penis upward to its full length, insert the applicator, press the button and withdraw it. Then roll the penis between your hands for at least 10 seconds so the medicine coats the urethral wall.
Stand or walk for ten minutes
After the pellet, sit or preferably stand or walk for about 10 minutes while the erection develops. An erection usually appears 5 to 10 minutes after the pellet and lasts roughly 30 to 60 minutes. The cream works in 5 to 30 minutes.
Injections rotate side and site
The injection goes into the upper side of the penis, along the third nearest the body, avoiding visible veins. Change both the side and the exact spot each time. Never straighten or reuse a bent needle, because needles can break.
Use a condom if pregnancy is possible
A condom is required if your partner is pregnant or could become pregnant, and it also reduces vaginal irritation, which is a reported reaction. Only latex condoms have been tested with the cream. Alprostadil is not a contraceptive and does not prevent infection.
Respect the frequency limits
The cream is used at most 2 to 3 times a week and once in 24 hours. Injections are at most once a day and three times a week. The pellet is at most 2 doses in 24 hours and 7 in 7 days.
Safety first
Safety, in full.
Caverject is an effective medicine — and like any medicine it carries risks. Your doctor screens for all of this before prescribing. Here's the honest picture, not just reassurance.
Side effects, by how often they happen
Stop and get urgent medical help if
seek medical help immediately
these need urgent attention, whatever the frequency
- An erection lasts 4 hours or more, which is priapism and a medical emergency that must not be left more than 6 hours
- Penile pain will not settle, or you notice a new bend, lump or hard patch in the penis
- You faint, feel close to fainting, or go dizzy with a sudden drop in blood pressure after a dose
- You get chest pain, or sudden weakness, numbness or trouble speaking
- Bleeding from the urethra will not stop, or there is blood in your urine
- Hives, a spreading rash or swelling appear, which can signal an allergic reaction
- A needle breaks and a fragment stays in the penis, which has needed surgical removal
Very common
very common (≥1/10)
more than 1 in 10 people
- Penile pain after intracavernosal injection, reported at least once by 30% of men and after 11% of injections
- Penile pain after the urethral pellet, in most cases rated mild or moderate
- Burning in the urethra after the urethral pellet
Common
common (≥1/100 to <1/10)
somewhere between 1 in 100 and 1 in 10 people
- Burning, tingling, throbbing or numbness in the penis, with the cream
- Redness, swelling, itching or general discomfort of the penis or genitals, with the cream
- Urethral pain with the cream, or minor urethral bleeding with the pellet
- An erection stronger or longer than expected, listed for all three forms
- Peyronie's disease, penile fibrosis, angulation or fibrotic nodules, with the injection and the pellet
- Bruising or a collection of blood at the injection site
- Headache, dizziness, symptomatic low blood pressure and muscle spasms, with the pellet
- Vaginal burning or itching in the partner, reported by about 6% of partners in the pellet studies
- Skin rash, with the cream
- Balanitis, inflammation of the head of the penis, with the cream
Uncommon
uncommon (≥1/1,000 to <1/100)
somewhere between 1 in 1,000 and 1 in 100 people
- Prolonged erection or priapism, listed at this frequency for all three forms
- Dizziness, fainting or a fall in blood pressure, listed for all three forms
- Painful erection, excessive rigidity, or loss of sensation in the penis
- Narrowing of the urethra, or inflammation of the urinary tract, with the cream
- Painful or frequent urination, urgency, blood in the urine or urethral bleeding
- Testicular or scrotal pain, swelling, redness or a lump, and pelvic or perineal pain
- Phimosis, ejaculation problems, or erectile dysfunction reported as a reaction
- Nausea, dry mouth, sweating, itching, rash, redness or a faster heartbeat
- Itching of the vulva or vagina in the partner, with the cream
- Widened pupils, extra heartbeats, a raised blood creatinine reading, or feeling weak
Rare
rare (≥1/10,000 to <1/1,000)
somewhere between 1 in 10,000 and 1 in 1,000 people
- Urinary tract infection, listed at this frequency for the urethral pellet
- Penile fibrosis, listed at this frequency for the urethral pellet
Very rare
very rare (<1/10,000)
fewer than 1 in 10,000 people
- Hives, known medically as urticaria, listed at this frequency for the urethral pellet
Frequency not known
not known (cannot be estimated from the available data)
reported after launch, but too rarely counted to put a number on
- Stroke, recorded in the injection product information as cerebrovascular accident
- Reduced blood supply to the heart muscle, recorded as myocardial ischaemia
Erectile dysfunction in adult men, as a local alternative to tablets.
- Apply the single-use dose to the opening at the tip of the penis 5–30 minutes before sex, following the leaflet's technique.
- The effect lasts around 1–2 hours.
- Maximum one dose per 24 hours, and no more than 2–3 doses per week.
- Wash hands after applying.
WHO SHOULD NOT TAKE IT, AND WHO NEEDS EXTRA CARE
- You have sickle-cell disease or sickle-cell trait, multiple myeloma or leukaemia, all of which predispose to priapism
- You have another condition predisposing to priapism, such as thrombocythaemia, polycythaemia, a tendency to venous thrombosis, a hyperviscosity syndrome, or past recurrent priapism
- You have a penile implant
- Your penis is anatomically deformed, including angulation, curvature, cavernosal fibrosis, Peyronie's disease or severe hypospadias
- You have urethritis or balanitis, or for the pellet a narrowing of the lower urethra
- You are allergic to alprostadil or to any other ingredient in the product
- A doctor has advised that sexual activity is inadvisable, for example with severe heart disease or unstable heart or circulation problems
- You have orthostatic hypotension, or a history of heart attack or fainting, which rule out the cream
- Your partner is pregnant or could become pregnant and a condom will not be used
- You are already using another erectile dysfunction treatment, including a PDE5 inhibitor tablet or another injected agent
When to seek urgent care
For severe, sudden or unexpected symptoms, call your local emergency number or go to the nearest emergency department. Then let your doctor know through your account chat.
Medicines and substances that interact
| MEDICINE OR SUBSTANCE | WHAT CAN HAPPEN | WHAT THE DOCTOR DOES |
|---|---|---|
| PDE5 inhibitor tablets (sildenafil, tadalafil, vardenafil) | Never studied together; both act on blood vessels, so cardiovascular risk could add up | Not used together; the prescriber keeps you on one treatment at a time |
| Other injected erection agents (papaverine, phentolamine, thymoxamine) | Raises the risk of priapism, a painful prolonged abnormal erection | Not combined; alprostadil is prescribed on its own |
| Blood pressure medicines and other vasodilators | Blood pressure can fall further, and the risk is higher in older men | Prescribed with caution, with clear warning about dizziness and fainting |
| Anticoagulants and antiplatelet drugs (warfarin, heparin) | More bleeding after an injection, and more urethral bleeding or blood in the urine | Prescriber weighs the bleeding risk and may rule out the injected route |
| Sympathomimetics, decongestants and appetite suppressants | May reduce the effect of alprostadil, so a working dose can seem to fail | Prescriber reviews the full medicine list before changing any dose |
| Latex condoms | Only latex has been tested with the cream; other materials may be damaged by it | Use a latex condom, which is required anyway if a partner could be pregnant |
Have a doctor review your caseThis is exactly what the doctor screens for before prescribing anything.
Read the full Caverject safety summaryEVIDENCE
What the clinical trials found
In the two New England Journal of Medicine programmes that registered these products, the MUSE Study Group trial of the urethral pellet and the Alprostadil Study Group trials of intracavernosal injection, both routes produced erections firm enough for intercourse in most men who had first responded to a supervised test dose.
1,511 men aged 27 to 88 with chronic erectile dysfunction of organic cause · single clinic visit, up to four test doses
Transurethral alprostadil tested at 125, 250, 500 and 1000 micrograms
Source: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)961 in-clinic responders who reported at least one home treatment · 3 months of home use
Transurethral alprostadil versus placebo, p<0.001; on average 7 of 10 doses were followed by intercourse
Source: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)683 men in a self-injection study of intracavernosal alprostadil · 6 months
Patients and partners rated the activity satisfactory after 87% and 86% of injections
Source: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group)the same 1,511-man transurethral alprostadil programme · clinic testing plus 3 months at home
The most common side effect; no man in that study had priapism or penile fibrosis
Source: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)men across three multicentre intracavernosal alprostadil studies · up to 6 months of self-injection
Alongside prolonged erection in 5% and penile pain in 50% of men, after 11% of injections
Source: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group)These are group averages from trials, not a forecast for any one person. Both routes were screened in clinic first, and the home figures describe only the men who had already responded to that supervised test dose, so they read better than the result an unselected group would get. The European Association of Urology also records that 41% to 68% of men stop intracavernous injections, most within the first two to three months, and that only about 30% stay on the urethral pellet long term, which is a fair reminder that tolerating a treatment matters as much as its measured efficacy.
ALTERNATIVES
Alprostadil vs the oral tablets usually tried first
| MEDICINE | HOW IT IS TAKEN | HOW OFTEN | TYPICAL DOSE RANGE | EU-AUTHORISED INDICATION | KEY EVIDENCE |
|---|---|---|---|---|---|
| Sildenafil | Tablet by mouth | As needed, maximum once a day | 25–100 mg | Erectile dysfunction in adult men; sexual stimulation is required | Dose-response study: improved erections 56%, 77%, 84% vs 25% placebo |
| Tadalafil | Tablet by mouth | As needed, or 5 mg once daily | 2.5–20 mg | Erectile dysfunction in adult males; sexual stimulation is required | Dose-response study: improved erections 67% and 81% vs 35% placebo |
| Vardenafil | Tablet by mouth | As needed, maximum once a day | 5–20 mg | Erectile dysfunction in adult men; sexual stimulation is required | Dose-response study: improved erections 66%, 76%, 80% vs 30% placebo |
Not sure which one fits your case? The doctor reviews your history and tells you.
Start consultation · €35ACCESS AND COST
Getting Caverject, and what it costs
Alprostadil is prescription-only in every EU country and no form of it is sold over the counter anywhere. Which form you can actually obtain varies a lot, so each row was read off that country's own medicines register rather than inferred from the EU-wide picture. The registers do not all publish the same thing: Spain, Portugal and Belgium record a marketing status per product, so those rows describe what is genuinely on sale, while Germany and Austria publish only whether an authorisation is currently valid, so their rows describe which forms are registered rather than which a pharmacy is stocking this week. Poland registers no alprostadil product for erectile dysfunction at all. The linked database is the current authority in every case.
What you pay Hi-Doctor
€35 one-off
Answer a few questions and a licensed EU doctor reviews your case in less than 2 hours on average. Refunded in full if it's not right for you.
What the pharmacy charges
Hi-Doctor does not sell, stock or dispense medicines and does not set their price. The medicine is paid for separately at the pharmacy, and the amount depends on the country, the pack size, whether a generic is available and whether your health system covers it. The official national database linked in the table publishes the current authorised price.
| COUNTRY | HOW IT IS SUPPLIED | COVERED BY THE HEALTH SYSTEM? | OFFICIAL SOURCE |
|---|---|---|---|
| Spain | Prescription-only; the injection carries a hospital-diagnosis restriction | See national criteria | AEMPS CIMA |
Show the other countries
| Germany | Prescription-only; injection, urethral stick and cream all hold a valid authorisation | Excluded from statutory health insurance | PharmNet.Bund AMIce |
|---|---|---|---|
| France | Prescription-only; the injections are liste I | Restricted — only for the organic causes listed in the official decision | Base de données publique des médicaments |
| Italy | Prescription-only; a specialist treatment plan is needed for cover | Restricted — AIFA Nota 75, intracavernosal injection only | AIFA Medicinali |
| Netherlands | Prescription-only | See national criteria | CBG-MEB Geneesmiddeleninformatiebank |
| Portugal | Prescription-only (MSRM); the injection and the cream each have at least one marketed presentation | See national criteria | INFARMED Infomed |
| Belgium | Prescription-only; the injection and the cream are commercialised, the dual-chamber cartridge is not | See national criteria | FAGG-AFMPS medicines database |
| Ireland | Prescription-only | See national criteria | HPRA Find a Medicine |
| Austria | Prescription-only (Rp); the urethral stick is recorded as marketed, the injection and the cream as authorised | See national criteria | BASG Medikamente Info Austria |
| Poland | Not marketed | — | Rejestr Produktów Leczniczych |
PRICING
You only pay if treatment is approved.
€35 for one sexual-health consultation. Paid once, with no recurring charge.
Sexual health
ONE-OFF
€35 one-off
One consultation, one doctor, one decision.
Nothing stored publicly, ever
Start consultation
Full refund if a review is not approved
WHAT'S INCLUDED
- Consultation reviewed by an EU-licensed doctor
- Electronic prescription if approved
- Full refund if not approved
Full refund if a review is not approved
If a review is not approved, we refund the €35 consultation fee in full.
Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.
HOW THE DOCTOR DECIDES
A licensed doctor reviews your case, not an algorithm
An EU-licensed doctor reads your questionnaire and answers in less than 2 hours on average.
If the doctor decides it is not safe to prescribe, the consultation fee is refunded in full.
Follow-up happens in the private chat inside your account, under GDPR. No WhatsApp, no SMS.
FREQUENTLY ASKED QUESTIONS
Questions about Caverject.
OTHER SEXUAL HEALTH TREATMENTS
Explore related treatments.
SOURCES
Where this information comes from
- 01
Vitaros 3 mg/g cream: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 02
Caverject Dual Chamber 20 micrograms: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 03
MUSE 500 microgramos bastoncillo uretral: Ficha Técnica — AEMPS, Spain, 2016
- 04
Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group) — New England Journal of Medicine 336(1):1-7, 1997
- 05
Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group) — New England Journal of Medicine 334(14):873-7, 1996
- 06
EAU Guidelines on Sexual and Reproductive Health, limited update March 2025 — European Association of Urology, 2025
- 07
Alprostadil: authorised medicines register (Caverject, Virirec and alprostadil cream marketed; MUSE authorised but not marketed) — AEMPS CIMA, Spain, 2026
- 08
Alprostadil: Vitaros 300 microgrammes cream and Edex 10/20 microgrammes marketed, liste I, restricted reimbursement — Base de données publique des médicaments, France, 2026
- 09
Alprostadil products authorised in Ireland: Caverject 10 and 20 micrograms, Vitaros 3 mg/g cream — medicines.ie, Irish medicines compendium, 2026
- 10
Register of medicinal products: no ATC G04BE01 alprostadil product registered for erectile dysfunction — Rejestr Produktów Leczniczych, Poland, 2026
- 11
Nota 75: reimbursement of alprostadil by intracavernosal injection limited to defined neurological criteria — AIFA, Gazzetta Ufficiale della Repubblica Italiana n. 7, 2017
- 12
§ 34 SGB V: medicines predominantly for erectile dysfunction excluded from statutory health insurance — Bundesministerium der Justiz, Germany, 2026
- 13
Regeling zorgverzekering: MUSE urethral stick 125 to 1000 micrograms listed on the Dutch medicines annex — Wetten.overheid.nl, Netherlands, 2026
- 14
Viagra (sildenafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2025
- 15
Cialis (tadalafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2025
- 16
Levitra (vardenafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2024
- 17
Alprostadil, human medicines with a currently valid German authorisation: Caverject and Caverject Impuls 10 and 20 micrograms (Pfizer Pharma GmbH plus parallel importers), Muse 500 and 1000 micrograms (Viatris Healthcare GmbH), Vitaros 300 micrograms/100 mg cream (The Simple Pharma Company Limited). The register publishes marketability, not whether a product is currently distributed. — BfArM AMIce, public part, via PharmNet.Bund, Germany, 2026
- 18
Alprostadilo: Caverject 0,01 and 0,02 mg/ml (Laboratórios Pfizer, Lda.) and Vitaros cream 0,3 mg/100 mg (Recordati Ireland Ltd.), each authorised with at least one marketed presentation — INFARMED Infomed, Portugal, 2026
- 19
Alprostadil: Caverject 10 and 20 micrograms and Vytaros 3 mg/g cream recorded as commercialised; Caverject Impuls 10 and 20 micrograms recorded as not commercialised — FAGG-AFMPS medicines database, Belgium, 2026
- 20
Alprostadil, ATC G04BE01: Muse 250, 500 and 1000 micrograms recorded as marketed; Caverject, Caverject Dual and Vitaros 3 mg/g cream authorised, with no marketing status published — BASG Medikamente Info Austria, Arzneispezialitätenregister, 2026
Reviewed by Hi-Doctor's medical team · Last reviewed 2026-07-27 · Next review due 2027-07-27
This page is educational information about a medicine, not a recommendation to take it and not a substitute for a medical consultation. Only a licensed doctor who has reviewed your history can decide whether a treatment is appropriate for you.
Find out if it's right for you
See if Caverject is appropriate for you.
Answer a few questions and a licensed EU doctor reviews your case in less than 2 hours on average. Refunded in full if it's not right for you.